HTG to price its IPO of 3.57 million shares between $13.00 and $15.00

Leerink Partners is the bookrunner; Canaccord Genuity, JMP to assist

By Devika Patel

Knoxville, Tenn., April 28 – HTG Molecular Diagnostics, Inc. will sell 3.57 million common shares in its initial public offering with a 30-day greenshoe option of 535,500 additional shares, according to a Form S-1/A filed Tuesday with the Securities and Exchange Commission. The company has registered up to $61.58 million of stock for the deal, which was announced on Dec. 31.

The shares will be sold at a price expected to fall between $13.00 and $15.00 per share.

Leerink Partners is the bookrunning manager. Canaccord Genuity and JMP Securities are the co-managers.

Proceeds will be used for clinical development, research and development, working capital and other general corporate purposes.

The Tucson, Ariz., company designs and markets a novel technology platform to facilitate the routine use of complex molecular profiling. The company intends to list its common stock on the Nasdaq under the symbol “HTGM.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.